Search

Your search keyword '"Najafi Fard, Saeid"' showing total 26 results
Start Over Author "Najafi Fard, Saeid" Search Limiters Academic (Peer-Reviewed) Journals
26 results on '"Najafi Fard, Saeid"'

2. Evaluation of the Local and Peripheral Immune Responses in Patients with Cystic Echinococcosis

Author

Petrone, Linda, primary, Najafi-Fard, Saeid, additional, Falasca, Laura, additional, Sbarra, Settimia, additional, Teggi, Antonella, additional, Nicastri, Emanuele, additional, Grillo, Lucia Rosalba, additional, Burocchi, Mirco, additional, Ettorre, Giuseppe Maria, additional, Ludovisi, Alessandra, additional, Colombo, Daniele, additional, Del Nonno, Franca, additional, and Goletti, Delia, additional

Published
2024
Full Text
View/download PDF

3. Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine

Author

Agrati, Chiara, Castilletti, Concetta, Goletti, Delia, Sacchi, Alessandra, Bordoni, Veronica, Mariotti, Davide, Notari, Stefania, Matusali, Giulia, Meschi, Silvia, Petrone, Linda, Aiello, Alessandra, Najafi Fard, Saeid, Farroni, Chiara, Colavita, Francesca, Lapa, Daniele, Leone, Sara, Agresta, Alessandro, Capobianchi, Maria, Ippolito, Giuseppe, Vaia, Francesco, and Puro, Vincenzo

Published
2022
Full Text
View/download PDF

6. Multi-omics approach to COVID-19: a domain-based literature review

Author

Montaldo, Chiara, Messina, Francesco, Abbate, Isabella, Antonioli, Manuela, Bordoni, Veronica, Aiello, Alessandra, Ciccosanti, Fabiola, Colavita, Francesca, Farroni, Chiara, Najafi Fard, Saeid, Giombini, Emanuela, Goletti, Delia, Matusali, Giulia, Rozera, Gabriella, Rueca, Martina, Sacchi, Alessandra, Piacentini, Mauro, Agrati, Chiara, Fimia, Gian Maria, Capobianchi, Maria Rosaria, Lauria, Francesco Nicola, and Ippolito, Giuseppe

Published
2021
Full Text
View/download PDF

9. A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients

Author

Petrone, Linda, Petruccioli, Elisa, Vanini, Valentina, Cuzzi, Gilda, Najafi Fard, Saeid, Alonzi, Tonino, Castilletti, Concetta, Palmieri, Fabrizio, Gualano, Gina, Vittozzi, Pietro, Nicastri, Emanuele, Lepore, Luciana, Antinori, Andrea, Vergori, Alessandra, Caccamo, Nadia, Cantini, Fabrizio, Girardi, Enrico, Ippolito, Giuseppe, Grifoni, Alba, and Goletti, Delia

Published
2021
Full Text
View/download PDF

11. Characterization of the immune impairment of tuberculosis and COVID-19 coinfected patients

Author

Najafi-Fard, Saeid, primary, Aiello, Alessandra, additional, Navarra, Assunta, additional, Cuzzi, Gilda, additional, Vanini, Valentina, additional, Migliori, Giovanni Battista, additional, Gualano, Gina, additional, Cerva, Carlotta, additional, Grifoni, Alba, additional, Sette, Alessandro, additional, Vaia, Francesco, additional, Palmieri, Fabrizio, additional, and Goletti, Delia, additional

Published
2023
Full Text
View/download PDF

12. Evaluation of the immunomodulatory effects of interleukin-10 on peripheral blood immune cells of COVID-19 patients: Implication for COVID-19 therapy

Author

Najafi-Fard, Saeid, primary, Petruccioli, Elisa, additional, Farroni, Chiara, additional, Petrone, Linda, additional, Vanini, Valentina, additional, Cuzzi, Gilda, additional, Salmi, Andrea, additional, Altera, Anna Maria Gerarda, additional, Navarra, Assunta, additional, Alonzi, Tonino, additional, Nicastri, Emanuele, additional, Palmieri, Fabrizio, additional, Gualano, Gina, additional, Carlini, Valentina, additional, Noonan, Douglas McClain, additional, Albini, Adriana, additional, and Goletti, Delia, additional

Published
2022
Full Text
View/download PDF

13. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy

Author

Alonzi, Tonino, primary, Aiello, Alessandra, additional, Petrone, Linda, additional, Najafi Fard, Saeid, additional, D’Eletto, Manuela, additional, Falasca, Laura, additional, Nardacci, Roberta, additional, Rossin, Federica, additional, Delogu, Giovanni, additional, Castilletti, Concetta, additional, Capobianchi, Maria Rosaria, additional, Ippolito, Giuseppe, additional, Piacentini, Mauro, additional, and Goletti, Delia, additional

Published
2021
Full Text
View/download PDF

14. ImmunosuppressiveTherapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients

Author

Picchianti-Diamanti, Andrea, primary, Aiello, Alessandra, additional, Laganà, Bruno, additional, Agrati, Chiara, additional, Castilletti, Concetta, additional, Meschi, Silvia, additional, Farroni, Chiara, additional, Lapa, Daniele, additional, Najafi Fard, Saeid, additional, Cuzzi, Gilda, additional, Cimini, Eleonora, additional, Grassi, Germana, additional, Vanini, Valentina, additional, Di Rosa, Roberta, additional, Salemi, Simonetta, additional, Nalli, Gabriele, additional, Salmi, Andrea, additional, Repele, Federica, additional, Altera, Anna Maria Gerarda, additional, Maffongelli, Gaetano, additional, Palazzolo, Claudia, additional, Vita, Serena, additional, Leone, Sara, additional, Puro, Vincenzo, additional, Capobianchi, Maria Rosaria, additional, Ippolito, Giuseppe, additional, Nicastri, Emanuele, additional, and Goletti, Delia, additional

Published
2021
Full Text
View/download PDF

17. Additional file 1 of Multi-omics approach to COVID-19: a domain-based literature review

Author

Montaldo, Chiara, Messina, Francesco, Abbate, Isabella, Antonioli, Manuela, Bordoni, Veronica, Aiello, Alessandra, Ciccosanti, Fabiola, Colavita, Francesca, Farroni, Chiara, Najafi Fard, Saeid, Giombini, Emanuela, Goletti, Delia, Matusali, Giulia, Rozera, Gabriella, Rueca, Martina, Sacchi, Alessandra, Piacentini, Mauro, Agrati, Chiara, Fimia, Gian Maria, Capobianchi, Maria Rosaria, Lauria, Francesco Nicola, and Ippolito, Giuseppe

Abstract

Additional file 1. Scoping review protocol. Working method and tools used by the domain groups. Table S1. Selected articles catalogued by domain. Table S2. Tables of evidence. A) Virus characterization and viral entry: B) Host signature: C) Pathways: D. Phenotypes. Table S3. B) Conceptual table: SARS-CoV-2 entry. Tabla S4. Immune response to SARS-CoV-2 infection in lung and other tissues (A), peripheral blood (B) and specific cell types in blood immune cells (C). Pathways, host signature (differentially expressed genes and proteins) and body districts, subset per specific omics data: host proteomics, bulk RNAseq and scRNAseq. Table S5. Pathogenic mechanisms in COVID-19 phenotype: SARS-CoV-2���host interactions in the lung. (A), DEG and DEP analysis in other organs and tissues (B) Hub genes and pathway of innate immune response (C), Comorbidities COVID-19 associated not sharing COVID-19 pathogenesis (D), Comorbidities associated and related to COVID-19 pathway (E). Omics and pathway involved were split by different phenotypes: severe, mild/asymptomatic and other Infections. Annexes: Annex 1���Report from Working Group 1: Molecular characterisation of the virus; Annex 2���Report from Working Group 2���Pathways; Annex 3���Report from Working Group 3- Host signatures; Annex 4���Report from Working Group 4���Phenotype. Glossary.

Published
2021
Full Text
View/download PDF

18. In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy

Author

Petrone, Linda, primary, Petruccioli, Elisa, additional, Alonzi, Tonino, additional, Vanini, Valentina, additional, Cuzzi, Gilda, additional, Najafi Fard, Saeid, additional, Castilletti, Concetta, additional, Palmieri, Fabrizio, additional, Gualano, Gina, additional, Vittozzi, Pietro, additional, Nicastri, Emanuele, additional, Lepore, Luciana, additional, Grifoni, Alba, additional, Antinori, Andrea, additional, Vergori, Alessandra, additional, Ippolito, Giuseppe, additional, Cantini, Fabrizio, additional, and Goletti, Delia, additional

Published
2021
Full Text
View/download PDF

19. Epidemic and pandemic viral infections: impact on tuberculosis and the lung

Author

Ong, Catherine Wei Min, primary, Migliori, Giovanni Battista, additional, Raviglione, Mario, additional, MacGregor-Skinner, Gavin, additional, Sotgiu, Giovanni, additional, Alffenaar, Jan-Willem, additional, Tiberi, Simon, additional, Adlhoch, Cornelia, additional, Alonzi, Tonino, additional, Archuleta, Sophia, additional, Brusin, Sergio, additional, Cambau, Emmanuelle, additional, Capobianchi, Maria Rosaria, additional, Castilletti, Concetta, additional, Centis, Rosella, additional, Cirillo, Daniela M., additional, D'Ambrosio, Lia, additional, Delogu, Giovanni, additional, Esposito, Susanna M.R., additional, Figueroa, Jose, additional, Friedland, Jon S., additional, Ho, Benjamin Choon Heng, additional, Ippolito, Giuseppe, additional, Jankovic, Mateja, additional, Kim, Hannah Yejin, additional, Rosales Klintz, Senia, additional, Ködmön, Csaba, additional, Lalle, Eleonora, additional, Leo, Yee Sin, additional, Leung, Chi-Chiu, additional, Märtson, Anne-Grete, additional, Melazzini, Mario Giovanni, additional, Najafi Fard, Saeid, additional, Penttinen, Pasi, additional, Petrone, Linda, additional, Petruccioli, Elisa, additional, Pontali, Emanuele, additional, Saderi, Laura, additional, Santin, Miguel, additional, Spanevello, Antonio, additional, van Crevel, Reinout, additional, van der Werf, Marieke J., additional, Visca, Dina, additional, Viveiros, Miguel, additional, Zellweger, Jean-Pierre, additional, Zumla, Alimuddin, additional, and Goletti, Delia, additional

Published
2020
Full Text
View/download PDF

20. Direct-acting antiviral therapy enhances total CD4+ and CD8+ T-cells responses, but does not alter T-cells activation among HCV mono-infected, and HCV/HIV-1 co-infected patients

Author

Najafi Fard, Saeid, primary, Schietroma, Ivan, additional, Corano Scheri, Giuseppe, additional, Giustini, Noemi, additional, Serafino, Sara, additional, Cavallari, Eugenio Nelson, additional, Pinacchio, Claudia, additional, De Girolamo, Gabriella, additional, Ceccarelli, Giancarlo, additional, Scagnolari, Carolina, additional, Vullo, Vincenzo, additional, and d’Ettorre, Gabriella, additional

Published
2018
Full Text
View/download PDF

21. Probiotics Differently Affect Gut-Associated Lymphoid Tissue Indolamine-2,3-Dioxygenase mRNA and Cerebrospinal Fluid Neopterin Levels in Antiretroviral-Treated HIV-1 Infected Patients: A Pilot Study

Author

Scagnolari, Carolina, primary, Corano Scheri, Giuseppe, additional, Selvaggi, Carla, additional, Schietroma, Ivan, additional, Najafi Fard, Saeid, additional, Mastrangelo, Andrea, additional, Giustini, Noemi, additional, Serafino, Sara, additional, Pinacchio, Claudia, additional, Pavone, Paolo, additional, Fanello, Gianfranco, additional, Ceccarelli, Giancarlo, additional, Vullo, Vincenzo, additional, and d’Ettorre, Gabriella, additional

Published
2016
Full Text
View/download PDF

23. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.

Author

Alonzi, Tonino, Aiello, Alessandra, Petrone, Linda, Najafi Fard, Saeid, D'Eletto, Manuela, Falasca, Laura, Nardacci, Roberta, Rossin, Federica, Delogu, Giovanni, Castilletti, Concetta, Capobianchi, Maria Rosaria, Ippolito, Giuseppe, Piacentini, Mauro, and Goletti, Delia

Subjects
COVID-19 treatment, ANTIVIRAL agents, DRUG repositioning, CYSTEAMINE, COVID-19, DISULFIDES, COVID-19 pandemic
Abstract

The ongoing pandemic of coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), needs better treatment options both at antiviral and anti-inflammatory levels. It has been demonstrated that the aminothiol cysteamine, an already human applied drug, and its disulfide product of oxidation, cystamine, have anti-infective properties targeting viruses, bacteria, and parasites. To determine whether these compounds exert antiviral effects against SARS-CoV-2, we used different in vitro viral infected cell-based assays. Moreover, since cysteamine has also immune-modulatory activity, we investigated its ability to modulate SARS-CoV-2-specific immune response in vitro in blood samples from COVID-19 patients. We found that cysteamine and cystamine decreased SARS-CoV-2-induced cytopathic effects (CPE) in Vero E6 cells. Interestingly, the antiviral action was independent of the treatment time respect to SARS-CoV-2 infection. Moreover, cysteamine and cystamine significantly decreased viral production in Vero E6 and Calu-3 cells. Finally, cysteamine and cystamine have an anti-inflammatory effect, as they significantly decrease the SARS-CoV-2 specific IFN-γ production in vitro in blood samples from COVID-19 patients. Overall, our findings suggest that cysteamine and cystamine exert direct antiviral actions against SARS-CoV-2 and have in vitro immunomodulatory effects, thus providing a rational to test these compounds as a novel therapy for COVID-19. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

24. Impact of Prior Influenza and Pneumoccocal Vaccines on Humoral and Cellular Response to SARS-CoV-2 BNT162b2 Vaccination.

Author

Puro, Vincenzo, Castilletti, Concetta, Agrati, Chiara, Goletti, Delia, Leone, Sara, Agresta, Alessandro, Cimini, Eleonora, Tartaglia, Eleonora, Casetti, Rita, Colavita, Francesca, Meschi, Silvia, Matusali, Giulia, Lapa, Daniele, Najafi Fard, Saeid, Aiello, Alessandra, Farrone, Chiara, Gallì, Paola, Capobianchi, Maria Rosaria, and Ippolito, Giuseppe

Subjects
HUMORAL immunity, SARS-CoV-2, INFLUENZA vaccines, COVID-19, VACCINATION, COVID-19 vaccines
Abstract

Vaccination against SARS-CoV-2 is considered the most effective method of prevention to contain the pandemic. While highly effective SARS-CoV-2 vaccines are being applied on a large-scale, whether and to what extent the strength of the vaccine-induced immune response could be further potentiated is still an object of debate. Several reports studied the effect of different vaccines on the susceptibility and mortality of COVID-19, with conflicting results. We aimed to evaluate whether previous influenza and/or pneumococcal vaccination had an impact on the specific immune response to the SARS-CoV-2 BNT162b2 mRNA vaccine. The study population consists of 710 workers from our Institute who completed the BNT162b2 schedule and have been tested at least once after the second dose, from 27 December 2020 up to 15 April 2021. Of these, 152 (21.4%) had received an influenza and 215 (30.3%) a concomitant influenza and pneumococcal vaccination, a median of 102 days before the second dose of BNT162b2. Overall, 100% of workers were tested for anti-Spike receptor-binding domain (anti-S/RBD) antibodies, 224 workers for neutralization titer (Micro-neutralization assay, MNA), and 155 workers for a spike-specific T cell interferon-γ response (IFN-γ). The levels of anti-S/RBD, MNA and IFN-γ were evaluated and compared according to sex, age, involvement in direct care of COVID-19 patients, and previous influenza/pneumococcal vaccination. At the univariate analysis, no statistically significant association was observed with regard to a previous influenza and pneumococcal vaccination. A significant lower anti-S/RBD response was observed according to an older age and male sex, while MNA titers were significantly associated to sex but not to age. At the multivariable analysis, workers receiving a concomitant influenza and pneumococcal vaccination or only influenza showed a 58% (p 0.01) and 42% (p 0.07) increase in MNA titers, respectively, compared to those who did not receive an influenza/pneumococcal vaccination. Female workers showed an 81% MNA and a 44% anti-S/RBD increase compared to male workers (p < 0.001). Compared to workers aged 21 to 49 years, those aged 50 or older were associated with a reduction in the anti-S/RBD (16%; p 0.005), MNA (31%; p 0.019), and IFN.g (32%) immune response. Maintaining the influenza and pneumococcal immunization program for the coming season, in which COVID-19 could still be spreading, remains strongly recommended to protect those who are more vulnerable and to limit the potential burden of these infections on the healthcare system. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

25. Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine

Author

Chiara, Agrati, Concetta, Castilletti, Delia, Goletti, Alessandra, Sacchi, Veronica, Bordoni, Davide, Mariotti, Stefania, Notari, Giulia, Matusali, Silvia, Meschi, Linda, Petrone, Alessandra, Aiello, Saeid, Najafi Fard, Chiara, Farroni, Francesca, Colavita, Daniele, Lapa, Sara, Leone, Alessandro, Agresta, Maria, Capobianchi, Giuseppe, Ippolito, Francesco, Vaia, Vincenzo, Puro, Eliana, Specchiarello, Agrati, Chiara, Castilletti, Concetta, Goletti, Delia, Sacchi, Alessandra, Bordoni, Veronica, Mariotti, Davide, Notari, Stefania, Matusali, Giulia, Meschi, Silvia, Petrone, Linda, Aiello, Alessandra, Najafi Fard, Saeid, Farroni, Chiara, Colavita, Francesca, Lapa, Daniele, Leone, Sara, Agresta, Alessandro, Capobianchi, Maria, Ippolito, Giuseppe, Vaia, Francesco, and Puro, Vincenzo

Subjects
Immunity, Cellular, Vaccines, Synthetic, COVID-19 Vaccines, Multidisciplinary, SARS-CoV-2, COVID-19 Vaccine, T-Lymphocytes, Vaccination, COVID-19, mRNA Vaccine, Antibodies, Viral, Antibodies, Neutralizing, Immunity, Humoral, T-Lymphocyte, Humans, mRNA Vaccines, BNT162 Vaccine, Human
Abstract

Vaccine is the main public health measure to reduce SARS-CoV-2 transmission and hospitalization, and a massive scientific effort worldwide resulted in the rapid development of effective vaccines. This work aimed to define the dynamics and persistence of humoral and cell-mediated immune response in Health Care Workers who received a two-dose BNT162b2-mRNA vaccination. Serological response was evaluated by quantifying anti-RBD and neutralizing antibodies while cell-mediated response was performed by a whole blood test quantifying Th1 cytokines (IFN-γ, TNF-α, IL-2) produced in response to Spike peptides. BNT162b2-mRNA vaccine induced both humoral and cell-mediated immune response against Spike in all HCW early after the second dose. After 12 weeks from vaccination, the titer of anti-RBD antibodies as well as their neutralization function decreased while the Spike-specific T-cells persisted at the same level as soon after vaccine boost. Of note, a correlation between cellular and humoral response persevered, suggesting the persistence of a coordinated immune response. The long lasting cell-mediated immune response after 3 months from vaccination highlight its importance in the maintaining of specific immunity able to expand again to fight eventual new antigen encountering.

Published
2022

26. Modulation of tryptophan/serotonin pathway by probiotic supplementation in human immunodeficiency virus-positive patients: preliminary results of a new study approach

Author

Noemi Giustini, Claudia Pinacchio, Giuseppe Corano Scheri, Maura Statzu, Sara Serafino, Annamaria Vullo, Andrea Mastrangelo, Saeid Najafi Fard, Luca Laghi, Giancarlo Ceccarelli, Gabriella De Girolamo, Vincenzo Vullo, Ivan Schietroma, Gabriella d'Ettorre, Eugenio Nelson Cavallari, Corano Scheri, Giuseppe, Najafi Fard, Saeid, Schietroma, Ivan, Mastrangelo, Andrea, Pinacchio, Claudia, Giustini, Noemi, Serafino, Sara, De Girolamo, Gabriella, Nelson Cavallari, Eugenio, Statzu, Maura, Laghi, Luca, Vullo, Annamaria, Ceccarelli, Giancarlo, Vullo, Vincenzo, and D’Ettorre, Gabriella

Subjects
0301 basic medicine, medicine.medical_specialty, Population, Inflammation, hiv, CD38, ido-1, Systemic inflammation, Bioinformatics, Peripheral blood mononuclear cell, lcsh:Physiology, ifn-γ, probiotics, serotonin, tryptophan, biochemistry, molecular biology, lcsh:Biochemistry, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, lcsh:QD415-436, education, IFN-γ, Original Research, education.field_of_study, lcsh:QP1-981, business.industry, Probiotics, IDO-1, tryptophan, serotonin, HIV, IFN-γ, Tryptophan, Serotonin pathway, 030104 developmental biology, Endocrinology, 030220 oncology & carcinogenesis, Serotonin, medicine.symptom, business
Abstract

Background: To date, no data are available regarding the effects of probiotics on the pathway of tryptophan/serotonin metabolism among human immunodeficiency virus (HIV) 1–infected individuals. Because a condition of dysbiosis might be responsible for the altered use of tryptophan described in this population, the aim of this study was to investigate the link between probiotic supplementation and serotonin levels in combined antiretroviral therapy–treated patients and the subsistence of an interplay with inflammation. Methods: We conducted a pilot study that included 8 HIV-positive subjects. We collected blood and fecal samples before and after 6 months of probiotic supplementation, to measure the level of serotonin in serum and tryptophan in stool, the expression of CD38 and HLA-DR on peripheral CD4+ T lymphocytes (as immune activation markers), the expression of indoleamine 2,3-dioxygenase 1 messenger RNA (mRNA) and IFN-γ mRNA (as markers of tryptophan metabolism and systemic inflammation). Results: After probiotic supplementation, we observed a significant increase in concentration of serum serotonin ( P = .008) and a decreased level of tryptophan in plasma. Moreover, a significant reduction in CD38 and HLA-DR expression on the surface of peripheral CD4+ T cells ( P = .008) and a reduced expression of indoleamine 2,3-dioxygenase 1 mRNA on peripheral blood mononuclear cells ( P = .04) were observed. Conclusions: Considering that this probiotic (Vivomixx® in EU; Visbiome® in USA) has an influence on tryptophan metabolism, larger studies on this topic are needed.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results